Pfizer enlists entire town in Brazil to study ongoing efficacy of its Covid vaccine

Toledo town, where the study will be conducted, has little to account for in terms of vaccine hesitancy

Anuj Pant
Thursday 07 October 2021 15:52
Comments
<p>File: A health worker administers a Covid vaccine dose to a resident as he takes a selfie, during mass vaccination at the Ilha Grande island, one of the most famous tourist spots in Rio de Janeiro state, Brazil</p>

File: A health worker administers a Covid vaccine dose to a resident as he takes a selfie, during mass vaccination at the Ilha Grande island, one of the most famous tourist spots in Rio de Janeiro state, Brazil

An entire town in Brazil will be inoculated by pharmaceutical company Pfizer to study the transmission of the coronavirus in a vaccinated population.

The study will be carried out among those above the age of 12 in the town of Toledo, west of the country’s Parana state, according to the company.

“The initiative is the first and only of its kind to be undertaken in collaboration with the pharmaceutical company in a developing country,” Pfizer said on Wednesday.

The observational study will help researchers find out the “real-life scenario” of the transmission of the coronavirus once an entire population is vaccinated.

It will aim to validate the real-world efficacy and safety of the Pfizer vaccine seen in clinical trials, Regis Goulart, a researcher at Porto Alegre’s Moinhos de Vento hospital, told Reuters.

Participants will be monitored for a year and will help answer questions such as the emergence of new variants and how long vaccines will prove to protect against Covid-19, Mr Goulart added.

The study will be done in partnership with Brazil’s national vaccination programme, local health authorities, a federal university and the Moinhos de Vento hospital.

Toledo, where the study will take place, has a population of 143,000 and little to account for in terms of vaccine hesitancy.

At least 98 per cent of its population has already received a first dose of a vaccine, primarily Pfizer, reported Reuters.

Around 56 per cent of the town is also fully vaccinated, with AstraZeneca and Sinovac vaccines being used as well, said municipal health secretary Gabriela Kucharski.

“Here we believe in science and we lament the almost 600,000 deaths from COVID-19 in Brazil,” Beto Lunitti, the town’s mayor, said at a press conference announcing the Pfizer study.

A similar study was earlier conducted in the smaller town of Serrana in Sao Paulo state. The study tested the CoronaVac jab, developed by China’s Sinovac Biotech.

Butantan Institute, a leading biomedical research centre in Brazil which conducted the study, said in May that mass vaccination reduced Covid-19 deaths by 95 per cent in the town, which has a population of 45,644 people.

The institute is considering extending the study for a third dose, according to Reuters.

Additional reporting by agencies

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in